INTANGIBLES - Intangible assets (Details) - USD ($) $ in Thousands |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2024 |
Dec. 31, 2023 |
Nov. 01, 2024 |
|
| INTANGIBLE ASSETS | |||
| Intangible assets - product licenses | $ 52,925 | $ 37,925 | |
| Accumulated Amortization | (17,919) | (14,495) | |
| Accumulated impairment loss | (3,143) | (3,143) | |
| Total | 31,863 | 20,287 | |
| Amortization expense | 3,424 | 3,767 | |
| Intangible asset impairment charge | 3,143 | ||
| Emrosi Agreement | |||
| INTANGIBLE ASSETS | |||
| Milestone payment after approval triggered | $ 15,000 | ||
| Cost of goods sold | |||
| INTANGIBLE ASSETS | |||
| Amortization expense | $ 3,400 | $ 3,800 | |
| Minimum | |||
| INTANGIBLE ASSETS | |||
| Estimated Useful Lives (Years) | 3 years | ||
| Maximum | |||
| INTANGIBLE ASSETS | |||
| Estimated Useful Lives (Years) | 15 years | ||
| X | ||||||||||
- Definition Accumulated amount of impairment of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. No definition available.
|
| X | ||||||||||
- Definition Amount of milestone payments payable which is triggered due to approval received from FDA under the license, collaboration, and assignment agreement. No definition available.
|
| X | ||||||||||
- Definition The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. No definition available.
|
| X | ||||||||||
- Definition Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|